The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

18 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.EBI
Slovak Academy Of Sciences
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.EBI
Universit£
Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.EBI
Gifu Pharmaceutical University
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.EBI
Gifu Pharmaceutical University
Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17ß-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.EBI
University Of Pennsylvania
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.EBI
Universitat Aut£Noma De Barcelona
Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-ß-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.EBI
University Of Toyama
Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.EBI
Gifu Pharmaceutical University
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.EBI
Gifu Pharmaceutical University
Overview of AKR1C3: Inhibitor Achievements and Disease Insights.EBI
China Pharmaceutical University
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.EBI
Kyushu University
Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity.EBI
Comenius University In Bratislava
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.EBI
University Of Hradec Kralove
Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.EBI
Slovak Academy Of Sciences
Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase.EBI
Universitat Aut£Noma De Barcelona
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.EBI
Gifu Pharmaceutical University